Obesity, metabolic syndrome, and type 2 diabetes: The low testosterone triangle
Listen to this article as a podcast episode
July 02, 2026 · 19:17
Obesity, metabolic syndrome, and type 2 diabetes form a clinically important low testosterone triangle because low testosterone is common across all three conditions. The relationship runs in both directions. Low testosterone is associated with visceral fat gain and insulin resistance, while excess adiposity and metabolic dysfunction further suppress testosterone production.
Find the cause before treating it
Choose a lab panel and get a clinical review with clear next steps.
Key takeaways
- Obesity is a major, modifiable driver of functional male hypogonadism. The two conditions reinforce each other: low testosterone is associated with more central fat, and excess fat further lowers testosterone.[1] [2]
- Metabolic syndrome is diagnosed when at least three of five findings are present: an enlarged waist, high triglycerides, low HDL cholesterol, raised blood pressure, and raised fasting glucose.[3] Erectile dysfunction is reported in 35% to 90% of men with diabetes.[4]
- Male hypogonadism is a syndrome, not a number. Persistent symptoms must be paired with consistently low morning testosterone, and LH and FSH are measured to tell primary from secondary hypogonadism.[5] [6]
- In the T4DM trial, adding testosterone to a lifestyle program reduced the share of men with type 2 diabetes at 2 years.[7] In a TRAVERSE substudy of men with hypogonadism, testosterone alone did not significantly slow progression from prediabetes to diabetes or improve glycemic control in men who already had diabetes.[8]
- Testosterone therapy has shown benefits on measures of obesity in hypogonadal men, with longer treatment often producing larger improvements.[1]
- Enclomiphene, an estrogen receptor antagonist, raised testosterone in men with secondary hypogonadism in early trials by increasing the body’s own production while maintaining testicular volume.[9] Larger placebo controlled trials are still needed.[9]
Why obesity and low testosterone reinforce each other
Obesity is one of the main drivers of functional male hypogonadism, and low testosterone and obesity tend to worsen each other through a cycle centered on visceral fat, the fat stored around the abdominal organs.[1] [2]
According to a 2015 review in Obesity Reviews, the relationship between testosterone and obesity runs in both directions, a pattern described as the hypogonadal obesity cycle, and weight loss can raise testosterone.[1] Excess adipose tissue increases aromatase activity. Aromatase converts testosterone to estradiol. In men with obesity, higher estradiol strengthens negative feedback at the hypothalamus and pituitary, suppresses LH signaling, and reduces testosterone production.
The visceral fat aromatase loop
Each condition makes the other harder to reverse. Low testosterone is associated with more fat mass, particularly central fat, and less lean mass, along with impaired glucose control and reduced insulin sensitivity.[1] The same review suggests that part of the benefit of testosterone treatment in obese hypogonadal men may come from more energy and motivation to stay active, which suggests that low testosterone can itself be a barrier to an active lifestyle.[1]
Why body composition changes matter
A 2013 meta analysis in the European Journal of Endocrinology found that weight loss in men with obesity raised both bound and unbound testosterone, raised LH and FSH, and lowered estradiol.[10] That pattern supports the view that obesity associated secondary hypogonadism is often functional rather than permanent.
How metabolic syndrome and testosterone drive each other
Metabolic syndrome and low testosterone are closely linked, and the evidence points to influence in both directions.[1] Metabolic syndrome is diagnosed when at least three of five findings are present: an enlarged waist, high triglycerides, low HDL cholesterol, raised blood pressure, and raised fasting glucose.[3] Insulin resistance, meaning the body does not respond normally to insulin so more insulin is needed to control blood sugar, often accompanies this cluster.
Each component pushes testosterone down
According to a 2024 review in The Lancet Diabetes & Endocrinology, low testosterone in men with obesity, type 2 diabetes, or advancing age is often functional: it occurs without identifiable disease of the hypothalamus, pituitary, or testes.[2] In obesity the pattern is hypogonadotropic, and weight loss raises both gonadotropins and testosterone, which places the suppression at the hypothalamus and pituitary rather than in the testes.[10] Central fat adds to this through aromatase driven conversion of testosterone to estradiol.[1]
Low testosterone also worsens metabolic syndrome
Low testosterone is associated with central fat gain, impaired glucose control, reduced insulin sensitivity, and dyslipidemia, and androgens act directly on fat, muscle, and liver metabolism.[1] This is why men with metabolic syndrome often present with sexual, hormonal, and metabolic symptoms at the same time, and why finding one of them is a reason to look for the others.
What type 2 diabetes changes and what testosterone cannot do
Type 2 diabetes is strongly linked to low testosterone, but testosterone therapy alone is not a diabetes treatment or a reliable diabetes prevention strategy.[2] [8] Prediabetes means blood sugar is above normal but below the diagnostic range for diabetes.
A 2021 randomized trial in The Lancet Diabetes & Endocrinology, T4DM, enrolled 1,007 men aged 50 to 74 with a waist of 95 cm or more, total testosterone of 14 nmol/L or lower without pathological hypogonadism, and impaired glucose tolerance or newly diagnosed type 2 diabetes.[7] All joined a lifestyle program, and after 2 years 12% of the testosterone group versus 21% of the placebo group had glucose values in the diabetes range.[7] A 2024 substudy of the TRAVERSE trial in JAMA Internal Medicine compared testosterone gel with placebo, without a structured lifestyle program, in men with hypogonadism at 316 US sites.[8] Among 1,175 men with prediabetes, progression to diabetes did not differ significantly between groups (10.1% versus 14.6% at 24 months; overall P = .49), and among 3,880 men with diabetes, testosterone did not increase glycemic remission or improve glucose or hemoglobin A1c compared with placebo.[8]
| Study | Intervention | Population | Main metabolic finding |
|---|---|---|---|
| T4DM[7] | Testosterone injections plus a lifestyle program, versus placebo plus the same program | 1,007 men aged 50 to 74 with abdominal obesity, testosterone of 14 nmol/L or lower, and impaired glucose tolerance or new type 2 diabetes | Fewer men with type 2 diabetes at 2 years (12% versus 21%) |
| TRAVERSE substudy[8] | Testosterone gel versus placebo, without a structured lifestyle program | 1,175 men with prediabetes and 3,880 with diabetes, all with hypogonadism | No significant difference in progression to diabetes, and no improvement in glycemic control or remission |
Low testosterone is common in type 2 diabetes, but testosterone therapy does not replace glucose lowering treatment or lifestyle care. When a man with prediabetes or diabetes is treated for hypogonadism, the reason is his symptoms and confirmed biochemical deficiency, not an expected effect on blood sugar.[2] [8]
Why erectile dysfunction is often the clinical intersection
Erectile dysfunction is common in men with diabetes and metabolic disease, and it often has more than one cause, including blood vessel damage, nerve damage, and low testosterone. The EAU guideline defines erectile dysfunction as the persistent inability to attain and maintain an erection sufficient for satisfactory sexual performance.[5]
A 2020 review in Current Vascular Pharmacology reported that erectile dysfunction affects 35% to 90% of men with diabetes, depending on the population studied, and described sexual dysfunction as an often overlooked microvascular complication of type 2 diabetes that originates in endothelial dysfunction.[4] That does not mean every case is hormonal. Testosterone deficiency is one contributor, and in men with functional hypogonadism testosterone therapy produces modest improvements in sexual function.[2]
Men who present with erectile dysfunction should therefore be checked for metabolic syndrome, type 2 diabetes, and low testosterone. If testosterone deficiency is suspected, the workup includes morning total testosterone, LH, FSH, and free testosterone when SHBG is likely to be altered, as it often is in obesity and diabetes. LH and FSH distinguish primary from secondary hypogonadism, and that distinction determines whether a man needs replacement therapy or may be a candidate for a fertility preserving option.[6] For the classification step, see Primary vs secondary hypogonadism. For lab interpretation, see The complete low testosterone testing guide.
How treatment affects body composition and weight
In hypogonadal men with obesity, testosterone therapy improves measures of obesity, partly through direct effects on fat and muscle and possibly through more energy for physical activity.[1] The 2015 Obesity Reviews analysis notes that the size of the effect may depend on the form of treatment, with longer term administration often producing greater improvements, and it presents testosterone as a possible adjunct to weight management in obese men with confirmed hypogonadism rather than a replacement for it.[1]
Better body composition is not the same as better glucose control. In the TRAVERSE substudy, changes in glucose and hemoglobin A1c were similar with testosterone and placebo in men with prediabetes or diabetes.[8] In T4DM, hematocrit rose above 54% in 22% of men on testosterone versus 1% on placebo, which the investigators noted might limit treatment, and longer term durability and safety were not established.[7]
Why “lose weight first” is often an incomplete plan
Weight loss can improve obesity associated secondary hypogonadism, but the testosterone gain from diet alone is modest.[10] Combined with how hard it is to keep weight off over years, that makes a “lose weight first” plan incomplete for many men whose symptoms persist.
In the 2013 meta analysis, which pooled 24 studies, a low calorie diet raised total testosterone by about 2.9 nmol/L on average, compared with about 8.7 nmol/L after bariatric surgery.[10] The amount of weight lost was the best predictor of the rise, and gains were larger in younger men without diabetes.[10] Men are often told to lose weight because testosterone is low, while low testosterone is associated with more fat mass and less lean mass, and treating it may improve energy and motivation for activity.[1]
Where Enclomiphene fits
Enclomiphene is an estrogen receptor antagonist studied for secondary hypogonadism. Instead of replacing testosterone, it blocks estrogen feedback at the hypothalamus, which raises gonadotropin signaling and prompts the testes to make more of their own testosterone.[9] Functional secondary hypogonadism means low testosterone caused by reversible suppression of the hypothalamic pituitary gonadal axis rather than testicular failure, which is the pattern this mechanism targets.
A 2009 review in IDrugs reported that in early trials enclomiphene restored testosterone in men with secondary hypogonadism while maintaining testicular volume, with possible preservation of sperm production, and that it had an unanticipated favorable effect on fasting glucose.[9] The authors called for placebo controlled randomized trials in hypogonadism associated with obesity and metabolic syndrome, so the metabolic evidence remains preliminary.[9] Enclomiphene does not help primary hypogonadism, in which the testes cannot respond to higher LH. If symptoms and labs do not improve, testosterone therapy remains an option. Because the choice depends on whether LH is low or high, confirming the diagnosis and its type comes first. For a broader treatment comparison, see Alternatives to TRT.
What this triangle means for cardiovascular risk, mortality, and COVID-19
Low testosterone in men is associated with higher cardiovascular risk and higher mortality, but an association does not show that low testosterone causes these outcomes or that treatment prevents them.[11] [12] [13]
A 2011 meta analysis in The Journal of Clinical Endocrinology & Metabolism linked lower endogenous testosterone to higher all cause and cardiovascular mortality in community studies of men, but found large differences between studies that likely reflected differences in the underlying health of the cohorts.[11] A 2010 study in Heart followed 930 men with confirmed coronary disease for about 7 years and found that low bioavailable testosterone was associated with more than double the hazard of death.[12] A 2011 study in the Journal of the American College of Cardiology followed 2,416 Swedish men aged 69 to 81 and found that those in the highest quartile of total testosterone, at or above 550 ng/dL, had a 30% lower risk of cardiovascular events over 5 years than men in the lower three quartiles.[13]
These associations fit the biology, since low testosterone travels with central obesity, insulin resistance, and dyslipidemia.[1] Testosterone therapy improves some intermediate markers, including insulin sensitivity, but trials have not shown that it prevents type 2 diabetes, and the mortality data remain observational.[2] [11]
In the TRAVERSE trial, published in 2023 in the New England Journal of Medicine, testosterone gel was noninferior to placebo for major adverse cardiac events over a mean follow up of 33 months in 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease.[14] Atrial fibrillation, acute kidney injury, and pulmonary embolism were more common with testosterone.[14] The trial supports cardiovascular safety. It does not show cardiovascular benefit, and it does not make testosterone a diabetes treatment.
COVID 19 added another layer. In a small observational study of men hospitalized with COVID 19 pneumonia, published in Andrology, lower testosterone was associated with worse clinical outcomes, including transfer to intensive care and death.[15] Low testosterone during acute illness may partly reflect the stress of the illness itself, so a level measured during infection should not be interpreted in isolation, and these data do not show that testosterone treatment helps.
Myth vs fact
Myth: If a man loses weight, testosterone will reliably normalize
Fact: Weight loss does raise testosterone in obesity associated secondary hypogonadism, but the size of the rise tracks the amount of weight lost. In a 2013 meta analysis, a low calorie diet raised total testosterone by about 2.9 nmol/L on average, compared with about 8.7 nmol/L after bariatric surgery, and the gain was smaller in men with diabetes.[10]
Myth: TRT prevents type 2 diabetes by itself
Fact: In T4DM, adding testosterone to a lifestyle program reduced the share of men with glucose in the diabetes range at 2 years, in men with testosterone of 14 nmol/L or lower who did not have pathological hypogonadism.[7] In the TRAVERSE substudy, testosterone gel alone did not significantly prevent progression from prediabetes or improve glycemic control in men with diabetes.[8]
Myth: Erectile dysfunction in diabetes is always hormonal
Fact: In men with type 2 diabetes, erectile dysfunction is largely a microvascular complication rooted in endothelial dysfunction.[4] Low testosterone can contribute, and testosterone therapy improves sexual function only modestly, so erectile dysfunction in a man with diabetes calls for evaluation of blood vessels, nerves, glucose control, and hormones rather than an assumption that the cause is hormonal.[2]
Myth: Low testosterone in obesity is just normal aging
Fact: Obesity and type 2 diabetes, along with aging itself, are major contributors to functional hypogonadism. Diagnosis still requires persistent symptoms plus low testosterone, not age alone.[2] [5]
Bottom line
Obesity, metabolic syndrome, and type 2 diabetes form a low testosterone triangle because each condition can suppress testosterone, and low testosterone is in turn associated with more visceral fat, poorer insulin sensitivity, and worse body composition.[1] According to the 2024 Lancet Diabetes & Endocrinology review, improving overall health remains the standard management strategy in functional hypogonadism.[2] Testosterone therapy can improve symptoms and body composition in correctly diagnosed men, but it is not a diabetes treatment, and men with secondary hypogonadism who want to preserve fertility may discuss options that raise the body’s own production. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.
Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs a man already has, interpreted by licensed providers. When appropriate, treatment is enclomiphene or the enclomiphene plus tadalafil tablet, and Veedma’s protocol uses enclomiphene first for secondary or functional hypogonadism. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.
References
- Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581-606. PMID: 25982085
- De Silva NL, Papanikolaou N, Grossmann M, et al. Male hypogonadism: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2024;12:761-774. PMID: 39159641
- Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5. PMID: 19805654
- Faselis C, Katsimardou A, Imprialos K, et al. Microvascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18:117-124. PMID: 31057114
- Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
- Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9:32-45. PMID: 33338415
- Bhasin S, Lincoff AM, Nissen SE, et al. Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial. JAMA Intern Med. 2024;184:353-362. PMID: 38315466
- Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12:109-19. PMID: 19204885
- Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168:829-43. PMID: 23482592
- Araujo AB, Dixon JM, Suarez EA, et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-19. PMID: 21816776
- Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821-5. PMID: 20959649
- Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58:1674-81. PMID: 21982312
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
- Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2021;9:88-98. PMID: 32436355
Low energy, low libido, or brain fog?
Order your lab panelStart with a lab panel
Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.
Order your lab panelPrefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD: Founder & CEO at Veedma
Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.